Efficacy of Nanofiber Sheets Incorporating Lenvatinib in a Hepatocellular Carcinoma Xenograft Model

• Published in: Nanomaterials (Basel, Switzerland) Vol. 12; no. 8; p. 1364
• Main Authors: Yoshida, Terufumi, Kaibori, Masaki, Fujisawa, Nanami, Ishizuka, Mariko, Sumiyama, Fusao, Hatta, Masahiko, Kosaka, Hisashi, Matsui, Kosuke, Suzuki, Kensuke, Akama, Tomoya O., Katano, Tayo, Yoshii, Kengo, Ebara, Mitsuhiro, Sekimoto, Mitsugu
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 15.04.2022; MDPI
• Subjects: Animals; Antibodies; Anticancer properties; Antitumor activity; Body weight; Cancer therapies; Controlled release; Drug delivery; drug delivery system; Drug delivery systems; Drug dosages; electrospun nanofiber sheet; FDA approval; Hepatitis; Hepatocellular carcinoma; HuH-7; lenvatinib; Liver cancer; Nanofibers; Oral administration; poly ε-caprolactone; Polycaprolactone; Prolongation; Sheets; Signal transduction; Survival; Sustained release; Tumors; Vascular endothelial growth factor; Xenografts; Xenotransplantation; United States > US; Japan; HuH-7; electrospun nanofiber sheet; drug delivery system; lenvatinib; poly ε-caprolactone

Lenvatinib has a high response rate in unresectable advanced hepatocellular carcinoma (HCC). In this study, we investigated whether lenvatinib-incorporating poly(ε-caprolactone) sheets (lenvatinib sheets) as a drug delivery system (DDS) exerted antitumor effects in a murine HCC model. The lenvatinib...